Angiotech Pharmaceuticals

In accordance with the implementation of the CCAA Plan, the Company entered into

Form: 8-K
Filed: May 16, 2011, 5:09 pm ET
Period: May 12, 2011
Importance: Major
Accession: 0001193125-11-141711
Document: 8-K
Exhibit 4.1: Indenture
Exhibit 4.2: Supplemental indenture
Exhibit 10.1: Credit agreement
Exhibit 10.2: Registration rights agreement
Exhibit 10.3: Angiotech Pharmaceuticals, Inc. 2011 stock incentive plan
Exhibit 10.4: Form of restricted share unit award agreement (for canadian participants)
Exhibit 10.5: Form of restricted stock award agreement (for U.S. participants)
Exhibit 10.6: Form of stock option/sar award agreement (for canadian participants)
Exhibit 10.7: Form of stock option/sar award agreement (for U.S. participants)
Exhibit 99.1: Press release

Signs a material agreement (1.01)
Ends a material agreement (1.02)
Takes on a new financial obligation (2.03)
Changes shareholder rights (3.03)
Reports a change in control (5.01)
Reports an executive or board change (5.02)
Amends its charter or bylaws (5.03)
Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

Similar companies

Same SIC code (3841) and public float not reported.